RxCell is a biotechnology company focused on therapeutic applications of induced pluripotent stem cells (iPSC).
RxCell has raised $4.6M in total funding. The most recent round was Series A. The last funding was announced in December 2023.
RxCell's investors include Regenosis, DMR Global Venture.
RxCell is headquartered in Singapore, Singapore.
RxCell is a biotechnology company focused on therapeutic applications of induced pluripotent stem cells (iPSC).
RxCell is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"RxCell — Funding & Investors." VCBacked, December 5, 2023, https://www.vcbacked.co/company/rxcell. Accessed August 14, 2026.
VCBacked. (2023). RxCell — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/rxcell
{{cite web |title=RxCell — Funding & Investors |url=https://www.vcbacked.co/company/rxcell |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated